CytRx Corporation (CYTR)

0.35
0.03 9.34
OTC
Prev Close 0.32
Open 0.32
Day Low/High 0.32 / 0.35
52 Wk Low/High 0.26 / 1.29
Volume 35.12K
Exchange OTC
Shares Outstanding 33.64B
Market Cap 11.10M
Div & Yield N.A. (N.A)
CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting

CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin, its lead...

Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation – CYTR

Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation – CYTR

Lieff, Cabraser, Heimann & Bernstein, LLP reminds investors of the May 14, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or acquired ...

Interesting CYTR Put And Call Options For December 20th

Interesting CYTR Put And Call Options For December 20th

Investors in CytRx Corp saw new options begin trading this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation...

CytRx Announces Research And Development Day And Webcast

CytRx Announces Research And Development Day And Webcast

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company will host a Research and Development Day on Friday, May 2, from 8:30...

Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering

Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering

Hagens Berman Sobol Shapiro LLP reminds investors of the May 13, 2014 deadline to file for lead plaintiff in the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) (“CytRx” or “the...

Why CytRx (CYTR) Stock Is Surging Today

Why CytRx (CYTR) Stock Is Surging Today

The biopharmaceutical R&D firm announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting

CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting

CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal...

Speculative Biotech Stock Offers Opportunity Amid Controversy

Speculative Biotech Stock Offers Opportunity Amid Controversy

CytRx has dug itself a deep hole recently, but the technical picture for the stock might be looking up.

CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation

CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation

Third graph, last sentence has been omitted. The corrected release reads: HAGENS BERMAN REMINDS CYTRX INVESTORS OF MAY 13, 2014 LEAD PLAINTIFF DEADLINE AND CONTINUED SECURITIES FRAUD INVESTIGATION ...

CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma

CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European...

Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of CytRx Corporation

Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of CytRx Corporation

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether CytRx Corporation (“CYTR” or the “Company”) and certain of its officers and directors made false and...

Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)

Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

CytRx Issues Statement Regarding Recent Lawsuits

CytRx Issues Statement Regarding Recent Lawsuits

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx ...

Interesting CYTR Put And Call Options For May 17th

Interesting CYTR Put And Call Options For May 17th

Investors in CytRx Corp saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTR options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

In This Trader's Market, a Week or More Is Now Long Term

In This Trader's Market, a Week or More Is Now Long Term

The stock market continued its volatile sell off on Monday from Friday's bearish action. We will be sufficiently oversold tomorrow on a red open to see a market turn to the upside..

CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma

CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and...

Whiplash: S&P Veers to All-Time High Before Crashing

Whiplash: S&P Veers to All-Time High Before Crashing

Volatility has been the theme of this stock market so far in 2014. Patience and opportunistic trading are of utmost importance.

Lieff Cabraser Announces Class Action Litigation Against CytRx Corporation - CYTR

Lieff Cabraser Announces Class Action Litigation Against CytRx Corporation - CYTR

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased the securities of CytRx Corporation (“CytRx” or the...

Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'

Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Investor Alert: Holzer & Holzer Announces Class Action Filed On Behalf Of Investors In CytRx Corporation

Investor Alert: Holzer & Holzer Announces Class Action Filed On Behalf Of Investors In CytRx Corporation

Holzer & Holzer, LLC announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation ...

Zeldes Haeggquist & Eck, LLP Announces Investigation Of CytRx Corporation

Zeldes Haeggquist & Eck, LLP Announces Investigation Of CytRx Corporation

Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into possible violations of the federal securities laws and other violations at CytRx ...

CytRx Establishes Research And Development Team And Opens New Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform

CytRx Establishes Research And Development Team And Opens New Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Felix Kratz, Ph.

CYTR July 19th Options Begin Trading

CYTR July 19th Options Begin Trading

Investors in CytRx Corp saw new options begin trading today, for the July 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 127 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Investors deserve answers from galena and cytrx about involvement in stock promo

Investors deserve answers from galena and cytrx about involvement in stock promo

Richard Pearson's expose, published yesterday on Seeking Alpha, pulls back the curtain on the shady world of paid stock touts. It's an excellent, well-researched story, mostly because of the documentation (emails and electronic signatures) Pearson obtained linking executives at Cytrx and Galena Biopharma to the publication of promotional articles under assumed names and without proper financial disclosure.

The Rosen Law Firm Announces Investigation Of Securities Claims Against CytRx Corporation - CYTR

The Rosen Law Firm Announces Investigation Of Securities Claims Against CytRx Corporation - CYTR

The Rosen Law Firm announces that it is investigating potential securities fraud claims against CytRx Corporation (NASDAQ: CYTR) resulting from allegations that CytRx may have paid outsiders to inflate its stock price...

CytRx Becomes Oversold (CYTR)

CytRx Becomes Oversold (CYTR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of April 19th Options Trading For CYTR

First Week of April 19th Options Trading For CYTR

Investors in CytRx Corp saw new options become available this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTR options chain for the new April 19th contracts and identified one put and one call contract of particular interest.

CytRx Reports 2013 Financial Results

CytRx Reports 2013 Financial Results

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the 12 months ended December 31, 2013, and also provided an overview...

TheStreet Quant Rating: D- (Sell)